Systemic safety of anti-VEGF drugs: a commentary

@article{Scott2015SystemicSO,
  title={Systemic safety of anti-VEGF drugs: a commentary},
  author={L. Scott and U. Chakravarthy and B. Reeves and C. Rogers},
  journal={Expert Opinion on Drug Safety},
  year={2015},
  volume={14},
  pages={379 - 388}
}
  • L. Scott, U. Chakravarthy, +1 author C. Rogers
  • Published 2015
  • Medicine
  • Expert Opinion on Drug Safety
  • Introduction: VEGF is a mediator of angiogenesis. Thus, concerns have been expressed following the use of VEGF inhibitors for the treatment of neovascular age-related macular degeneration (nAMD). Ranibizumab, and more recently aflibercept, are VEGF inhibitors licensed for the treatment of nAMD. Bevacizumab is also used but unlicensed for this application. Areas covered: A non-systematic review of nAMD trials was undertaken to investigate four outcomes: all-cause mortality, all systemic serious… CONTINUE READING
    14 Citations
    Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
    • 13
    • PDF
    Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model
    • 4
    • PDF

    References

    SHOWING 1-10 OF 38 REFERENCES
    Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
    • 512
    • PDF
    Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    • 1,060
    • Highly Influential
    • PDF
    Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    • 142
    • Highly Influential
    Ranibizumab for neovascular age-related macular degeneration.
    • 1,948
    • PDF